53. OnabotulinumtoxinA in the treatment for chronic migraine: Four years follow-up in the experience of Careggi Hospital

The purpose of this study was to evaluate the efficacy, safety and tolerability of onabotulinumtoxinA as prophylactic therapy in patients with “refractory” chronic migraine (CM). We analyzed 76 patients (12M, 64F; mean age 52 years- 23–82) with CM resistant to conventional syntomatic and/or prophylactic polytherapy, afferent to the Regional Reference Center of Chemical denervation (RRCCd) of Careggi Hospital, in 2011–2014 period. Each patient was treated (after informed consent) with onabotulinum-toxin A (dose-range 155–195U) every 3 months, according to Blumenfeld’s protocol. We considered the following parameters: frequence (F) and intensity (I) of migraine attacks and drug’s use (D). We employed an ANOVA for repeated measures to test for changes across time. All 76 patients received the toxin treatment at least four time: 44/76 responded to treatment (38F-6M).The parameters F, I, D showed a progressive and gradual decline with time ( p OnabotulinumtoxinA represents a safe, tollerated and effective prophylactic treatment in “refractory” chronic migraine.